Former FDA Official Will Succeed Industry Leader Jim Greenwood on June 1 as Leader of World’s Largest Biotechnology Advocacy Association

New Jersey-based Legend Biotech, a clinical stage oncology biotech company, filed with the U.S. Securities and Exchange Commission on Wednesday to raise up to $100 million in an initial public offering.

Genentech, a Roche company, announced positive results from the Phase II CITYSCAPE clinical trial in PD-L1-positive metastatic non-small cell lung cancer (NSCLC). The study was evaluating a new checkpoint inhibitor tiragolumab and its checkpoint inhibitor Tecentriq (atezolizumab) compared to Tecentriq alone.

Johnson & Johnson’s BCMA-targeting CAR-T therapy banished tumors in 86% of patients with advanced multiple myeloma in a phase 1b study, improving on the 66% figure posted five months ago. The treatment could help patients who face a “dismal prognosis” and generally live for just a few months with standard of care.

One year after betting $1.05 billion on Peloton Therapeutics, Merck is unveiling data from a phase 2 study of a HIF-2α inhibitor picked up in that deal—and it’s promising.

Bristol Myers Squibb’s BCMA-targeting CAR-T therapy shrank tumors in nearly three-quarters of relapsed multiple myeloma patients and eliminated them in one-third. And the treatment, picked up in the company’s $74 billion Celgene buyout, could help patients who are “truly at the end of treatment options.”

QurAlis has officially launched under a $42 million series A round with a focus on new therapies for amyotrophic lateral sclerosis (ALS) and genetically related frontotemporal dementia (FTD).

The U.K.’s Wellcome Trust has spun out a new non-profit with a hefty seed fund and some big names to battle against “the most pressing global health challenges of our time.”

California-based Kriya Therapeutics announced on Tuesday that it concluded an $80.5 million Series A financing round, led by QVT, Dexcel Pharma, Foresite Capital, Bluebird Ventures, Narya Capital, Amplo, Paul Manning, and Asia Alpha. The company, which was founded in 2019, has a pipeline that includes multiple AAV-based gene therapies for the treatment of type 1 and type 2 diabetes, as well as obesity.

CAMBRIDGE, Mass.– Dyno Therapeutics, a biotechnology company applying artificial intelligence (AI) to gene therapy, today announced two presentations and a poster at the American Society of Gene and Cell Therapy (ASGCT) conference being held as a virtual meeting on May 12-15, 2020.